However, much data exists on neoadjuvant anti-HER-2 therapy and chemotherapy in patients with HER-2-positive breast cancer in some countries (Hurvitz et al., 2018; Fasching et al., 2019). This evidence concerns the gene ERBB2 and breast cancer.